Pharmaceuticals, Biotechnology and Life Sciences
The U.S. Food and Drug Administration (FDA) has approved Sanofi’s and Regeneron Pharmaceuticals’s Kevzara (sarilumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX).
Merck, one of the worlds most renown science and technology companies, summoned experts from worlds organizations such as UN, UNICEF, UNAIDS, World Obesity Federation and McKinsey at the the company’s headquarters in Darmstadt, Germany, to discuss questions about the most urgent threats to our children’s long-term health, or what can be done both inside and outside the classroom? And how do schools, parents and communities share responsibility?
Arix Bioscience on Friday said that its new business group, Iterum, has raised $65 million by closing a Series B investment round. “Arix is delighted to have led this $65m funding round comprising many of the biotech sector’s leading specialist investors,” said…
The U.S. Food and Drug Administration (FDA) expanded the approved indication for Vertex Pharmaceuticals’ Kalydeco (ivacaftor) for the treatment of cystic fibrosis (CF).
The Saudi Food & Drug Authority (SFDA) has approved Swedish Orphan Biovitrum’s (Sobi) Elocta (efmoroctocog alfa), a recombinant human factor VIII Fc-fusion protein with an extended half-life, for the treatment of haemophilia A.
U.S. Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ Kalydeco (ivacaftor) for use in people with cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
The Saudi Food and Drug Administration (SFDA) has approved Swedish Orphan Biovitrum’s (Sobi) Orfadin (nitisinone) capsules in all strengths (2 mg, 5 mg, 10 mg and 20 mg) for the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.
Its have been three years since Ice bucket challenge went viral promoting awareness of amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease and encourage donations to research.
Novartises Rydapt has been approved by the FDA for the treatment of acute myeloid leukemia, and for treating adults with advanced systemic mastocytosis.
Sanofi Chief Executive Officer, Olivier Brandicourt, said that the company has started the year with robust growth driven by Specialty Care and Vaccines as well as good performance in Emerging Markets.